bullish
Keytruda Approved for Lung Cancer Treatment in China - A Review of PD-1 Battle Field
641 Views11 Apr 2019 09:11
Anti-PD-1 monoclonal antibody (mAb) is a hotly contested immunotherapy area in China, with seven companies working on clinical trials covering...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- ECM Weekly (27 April 2019) - Luckin, Duiba, Leong Hup, ARA US Hosp, Douyu, So-Young, Yunji27 Apr 2019
- ECM Weekly (18 April 2019) - Duiba Group, MabPharm, Huami, Cofco Meat, Innovent, Times China18 Apr 2019
- Innovent Biologics (信达生物) Placement - Selling upon Lock-Up Expiry16 Apr 2019
- Innovent Biologics (信达生物) IPO: Limited Upside Despite Strong Cornerstones (Part 3)16 Oct 2018
- Innovent Biologics (信达生物) IPO: Pricing the PD-1 and Biosimilars Competition (Part 2)10 Oct 2018
x